Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 11 July 2018

Indication(s)

Aerius 5 mg film-coated tablets
Aerius 5 mg orodispersible tablets:

Aerius is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
- allergic rhinitis
- urticaria


Aerius 2.5 mg orodispersible tablets:
Aerius is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:
- allergic rhinitis
- urticaria


Aerius 0.5 mg/ml oral solution:
Aerius is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:
- allergic rhinitis
- urticaria

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000313
Orphan designation No
Date First Approved 15-01-2001
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme B.V.